Identifying and Targeting TNF Signaling in Idiopathic Multicentric Castleman's Disease.
PubMed 39908436 · doi:10.1056/NEJMc2412494
Cited by
- supports A patient with refractory severe Castleman disease in Vancouver achieved remission following treatment with the TNF inhibitor adalimumab, published in the New England Journal of Medicine.
- supports In Castleman disease, activated CD4-positive T cells produce excessive amounts of tumor necrosis factor (TNF).